Jeffrey Rubens

777 total citations
22 papers, 505 citations indexed

About

Jeffrey Rubens is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Jeffrey Rubens has authored 22 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Jeffrey Rubens's work include Cancer Mechanisms and Therapy (11 papers), Chromatin Remodeling and Cancer (11 papers) and Protein Degradation and Inhibitors (6 papers). Jeffrey Rubens is often cited by papers focused on Cancer Mechanisms and Therapy (11 papers), Chromatin Remodeling and Cancer (11 papers) and Protein Degradation and Inhibitors (6 papers). Jeffrey Rubens collaborates with scholars based in United States, Canada and Germany. Jeffrey Rubens's co-authors include Eric H. Raabe, Charles G. Eberhart, Elizabeth A. Stemmler, Anne McBride, Shugaku Takeda, Todd D. Westergard, Jill K. Fisher, Stanley J. Korsmeyer, Satoru Sasagawa and James J. Hsieh and has published in prestigious journals such as Journal of Biological Chemistry, Genes & Development and Blood.

In The Last Decade

Jeffrey Rubens

22 papers receiving 499 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Rubens United States 10 399 91 78 69 52 22 505
Sarah Fattet France 9 263 0.7× 148 1.6× 30 0.4× 56 0.8× 60 1.2× 14 412
Jeffrey Knipstein United States 9 328 0.8× 94 1.0× 95 1.2× 56 0.8× 38 0.7× 15 444
John F. Schwerkoske United States 8 174 0.4× 135 1.5× 26 0.3× 26 0.4× 54 1.0× 13 343
Tetsuya Otsuki Japan 11 383 1.0× 51 0.6× 156 2.0× 35 0.5× 76 1.5× 24 561
Dailia B. Francis United States 4 323 0.8× 37 0.4× 25 0.3× 53 0.8× 90 1.7× 5 403
Roser Calvo United States 9 243 0.6× 56 0.6× 89 1.1× 17 0.2× 75 1.4× 17 404
Julianne Behnke Germany 9 304 0.8× 195 2.1× 60 0.8× 96 1.4× 77 1.5× 13 425
Tingxun Lu China 10 157 0.4× 57 0.6× 158 2.0× 41 0.6× 111 2.1× 22 365
Liliana Villafania United States 9 206 0.5× 71 0.8× 81 1.0× 30 0.4× 162 3.1× 17 418
David Eaves United States 8 191 0.5× 33 0.4× 53 0.7× 307 4.4× 35 0.7× 9 539

Countries citing papers authored by Jeffrey Rubens

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Rubens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Rubens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Rubens more than expected).

Fields of papers citing papers by Jeffrey Rubens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Rubens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Rubens. The network helps show where Jeffrey Rubens may publish in the future.

Co-authorship network of co-authors of Jeffrey Rubens

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Rubens. A scholar is included among the top collaborators of Jeffrey Rubens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Rubens. Jeffrey Rubens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eberhart, Charles G., et al.. (2024). ATRT-17. INHIBITING THE MAP KINASE PATHWAY WITH MEK INHIBITOR MIRDAMETINIB SUPPRESSES CANCER GROWTH IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology. 26(Supplement_4). 0–0. 1 indexed citations
2.
Eberhart, Charles G., et al.. (2023). ATRT-04. TARGETING THE COREST COMPLEX HELPS REPROGRAM AT/RT’S ABNORMAL EPIGENETIC LANDSCAPE TOWARD A DIFFERENTIATION PHENOTYPE. Neuro-Oncology. 25(Supplement_1). i1–i2. 1 indexed citations
3.
Rubens, Jeffrey, Susan Chi, Tom Rosenberg, et al.. (2023). Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. Neoplasia. 37. 100880–100880. 15 indexed citations
4.
Wang, Sabrina, Jesse Alt, Micah J. Maxwell, et al.. (2022). Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. Cell Death and Disease. 13(4). 410–410. 5 indexed citations
5.
6.
7.
Maxwell, Micah J., Antje Arnold, Lijun Chen, et al.. (2021). Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant Glioma. Molecular & Cellular Proteomics. 20. 100123–100123. 5 indexed citations
8.
Yuan, Ming, David T. White, Linda Resar, et al.. (2020). Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. Neuro-Oncology. 23(5). 770–782. 20 indexed citations
9.
Rubens, Jeffrey, et al.. (2020). MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. Journal of Neuropathology & Experimental Neurology. 79(7). 746–753. 5 indexed citations
10.
Wang, Sabrina, Brad Poore, Jesse Alt, et al.. (2019). Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Clinical Cancer Research. 25(19). 5925–5936. 23 indexed citations
11.
Poore, Brad, Ming Yuan, Antje Arnold, et al.. (2018). Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro-Oncology. 21(2). 252–263. 22 indexed citations
12.
Rubens, Jeffrey, Sabrina Wang, Melanie Weingart, et al.. (2017). The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro-Oncology. 19(10). 1361–1371. 17 indexed citations
13.
Miyahara, Hiroaki, Sridevi Yadavilli, Manabu Natsumeda, et al.. (2017). The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Letters. 400. 110–116. 51 indexed citations
14.
Cooper, Stacy, Jeffrey Rubens, & Joann Bodurtha. (2016). Five Pediatric Cancers – Update on Genetic Implications. Current Pediatric Reviews. 13(1). 42–48. 3 indexed citations
15.
Weingart, Melanie, Jacquelyn J. Roth, Marianne Hütt-Cabezas, et al.. (2014). Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget. 6(5). 3165–3177. 58 indexed citations
16.
Rubens, Jeffrey, Yasmin Gosiengfiao, Tadanori Tomita, David A. Jacobsohn, & Jason Fangusaro. (2011). Long‐term survival in a pediatric patient with supratentorial primitive neuro‐ectodermal tumor and extraneural metastasis at diagnosis. Pediatric Blood & Cancer. 57(2). 341–344. 1 indexed citations
17.
Takeda, Shugaku, David Y. Chen, Todd D. Westergard, et al.. (2006). Proteolysis of MLL family proteins is essential for Taspase1-orchestrated cell cycle progression. Genes & Development. 20(17). 2397–2409. 133 indexed citations
18.
Hsieh, James J., Shugaku Takeda, David Y. Chen, et al.. (2006). Proteolysis of MLL Family Proteins Is Essential for Taspase1−Orchestrated Cell Cycle Progression.. Blood. 108(11). 769–769. 6 indexed citations
19.
McBride, Anne, et al.. (2005). Arginine Methylation of Yeast mRNA-binding Protein Npl3 Directly Affects Its Function, Nuclear Export, and Intranuclear Protein Interactions. Journal of Biological Chemistry. 280(35). 30888–30898. 93 indexed citations
20.
Ritter, Matthew R., Stacey K. Moreno, Michael I. Dorrell, et al.. (2003). Identifying Potential Regulators of Infantile Hemangioma Progression through Large-scale Expression Analysis: A Possible Role for the Immune System and Indoleamine 2,3 Dioxygenase (IDO) during Involution. Lymphatic Research and Biology. 1(4). 291–299. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Fattet Breakdown of academic impact, for papers by Jeffrey Knipstein Breakdown of academic impact, for papers by John F. Schwerkoske Breakdown of academic impact, for papers by Tetsuya Otsuki Breakdown of academic impact, for papers by Dailia B. Francis Breakdown of academic impact, for papers by Roser Calvo Breakdown of academic impact, for papers by Julianne Behnke Breakdown of academic impact, for papers by Tingxun Lu Breakdown of academic impact, for papers by Liliana Villafania Breakdown of academic impact, for papers by David Eaves
Rankless by CCL
2026